KRAS and NRAS Screen
Also known as: RAS Panel, KRAS and NRAS Gene Test« Back to test list
The presence of specific activating mutations in the KRAS and NRAS genes in certain malignancies (for example, metastatic colorectal cancer) indicates a reduced likelihood of treatment response to anti-EGFR therapy.
A normal test result (no mutations) indicates that the patient’s tumour is likely to respond to anti-EGFR therapies. An abnormal test result (specific mutations identified) indicates that the tumour is likely to be resistant to anti-EGFR therapies.
This is an assay for non-heritable mutations. It does not raise issues of ethics or consent that are different from most other investigations ordered in the routine care of a patient.
Pyrosequencing of targeted mutations in the KRAS and NRAS genes. The most common mutations are tested for initially (codon 12 and 13 of KRAS), followed by testing for activating mutations in codons 61 and 146 of KRAS, and 12, 13 and 61 of NRAS.
This test is usually requested by an oncologist. Please use the specific request form (see link below).
Formalin fixed, paraffin-embedded tissue (FFPE) – 10 sections of 4 uM thickness, dried overnight at 37 degrees onto charged/coated slides.
Please stain the first section with H&E, and label each slide with patient and block identifiers. Label the unstained sections sequentially (slides 2-10). The request should be accompanied by complete Somatic Mutation Test Request Form and a copy of the original histopathology report.